2021ASH 静脉血栓栓塞症管理指南：癌症患者的预防和治疗

2021-02-23 美国血液病学会 Blood Adv . 2021 Feb 23;5(4):927-974

在癌症患者中，静脉血栓栓塞（VTE）是常见的并发症。静脉血栓栓塞症(VTE)是癌症患者中常见的并发症。癌症和VTE患者的发病和死亡风险明显增加。美国血液学学会(ASH)的这些循证指南旨在支持患者、临床

中文标题：

英文标题：

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

发布机构：

美国血液病学会

发布日期：

2021-02-23

简要介绍：

在癌症患者中，静脉血栓栓塞（VTE）是常见的并发症。静脉血栓栓塞症(VTE)是癌症患者中常见的并发症。癌症和VTE患者的发病和死亡风险明显增加。美国血液学学会(ASH)的这些循证指南旨在支持患者、临床医生和其他卫生保健专业人员做出预防和治疗癌症患者静脉血栓栓塞症的决定。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=1a1741c0020e111b, title=2021ASH 静脉血栓栓塞症管理指南：癌症患者的预防和治疗, enTitle=American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer, guiderFrom=Blood Adv . 2021 Feb 23;5(4):927-974, authorId=0, author=, summary=在癌症患者中，静脉血栓栓塞（VTE）是常见的并发症。静脉血栓栓塞症(VTE)是癌症患者中常见的并发症。癌症和VTE患者的发病和死亡风险明显增加。美国血液学学会(ASH)的这些循证指南旨在支持患者、临床, cover=https://img.medsci.cn/2021315/1615737691385_2020535.jpg, journalId=0, articlesId=null, associationId=25, associationName=美国血液病学会, associationIntro=美国血液病学会---是全球最大的关于血液疾病病因及治疗的专业协会。其使命为通过促进血液学的研究、临床护理、教育、培训及宣传而进一步促进对血液、骨髓、免疫、凝血及脉管系统疾病的了解、诊断与防治。ASH的官方杂志为《血液》，是该领域被引用最多的同行评议杂志，周刊。, copyright=0, guiderPublishedTime=Tue Feb 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>在癌症患者中，静脉血栓栓塞（VTE）是常见的并发症。静脉血栓栓塞症(VTE)是癌症患者中常见的并发症。癌症和VTE患者的发病和死亡风险明显增加。美国血液学学会(ASH)的这些循证指南旨在支持患者、临床医生和其他卫生保健专业人员做出预防和治疗癌症患者静脉血栓栓塞症的决定。</p>, tagList=[TagDto(tagId=57456, tagName=静脉血栓栓塞症)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=57456, guiderKeyword=静脉血栓栓塞症, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=18261, appHits=498, showAppHits=0, pcHits=1510, showPcHits=17763, likes=7, shares=47, comments=39, approvalStatus=1, publishedTime=Mon Mar 15 00:36:48 CST 2021, publishedTimeString=2021-02-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 15 00:01:38 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 13:42:31 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=美国血液学会2021年静脉血栓栓塞治疗指南：癌症患者的预防和治疗.pdf)])

美国血液学会2021年静脉血栓栓塞治疗指南：癌症患者的预防和治疗.pdf

下载请点击：

评论区 (29)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
2022-04-26 su_yi_fei

***

84 0
[GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
2021-12-13 1235354bm69暂无昵称

学习了

88 0
[GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
2021-12-13 1235354bm69暂无昵称

学习了

112 0
[GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
2021-12-13 1235354bm69暂无昵称

学习了

119 0
[GetPortalCommentsPageByObjectIdResponse(id=1214688, encodeId=745f121468819, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:28:36 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079444, encodeId=e34110e944403, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:49:59 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079441, encodeId=db2610e9441f5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:41 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079440, encodeId=1a7e10e944036, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8e12400716, createdName=1235354bm69暂无昵称, createdTime=Mon Dec 13 09:48:30 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078259, encodeId=052b10e825916, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:34:34 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
2021-12-09 一己怀

学习了

101 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2021ASH 静脉血栓栓塞症管理指南：癌症患者的预防和治疗

相关指南

拓展阅读

科室

工具

服务